A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

Clinical Infectious Diseases

Volumn 33, Issue 9, 2001, Pages 1447-1454

  Ally, R ^a,h   Schurmann D ^b   Kreisel, W ^c,h   Carosi, G ^d,h   Aguirrebengoa, K ^e,h   Dupont, Bertrand ^f   Hodges, M ^g   Troke, P ^g   Romero, A J ^g   Bingham, J S ^h   Sola Boneta, J ^h   De Rienzo, B ^h   Dinsmore, W W ^h   Dupont, B ^h   Fatkenheuer, M G ^h   Garsia, R J ^h   Fountas, D ^h   Gritti, F ^h   Hawkins, D A ^h   Heise, W ^h   Jarauratanasirikul, S ^h   Johnson, D W ^h   Johnson, M ^h   Lacoste, D ^h   Lawrence, R H ^h   lowenthal, R ^h   Madej, G ^h   Marriott, D ^h   Menichetti, F ^h   Moroni, M ^h   Mulcahy, F M ^h   Narciso, P ^h   Raffi, F ^h   Reiger, M A ^h   Reynes, J H R ^h   Rivera, I O ^h   Dabballa Radresa, P ^h   Sambeat Radresa, M A ^h   Santamaria, J M ^h   Savchenko, V G ^h   Schwegler, U ^h   Shahmanesh, M ^h   Simjee, A E ^h   Stoehr, A ^h   Supparatpinyo, K ^h   Sze Peng, B A ^h   Tansuphaswadikul, S ^h   De La Torre Cisneros, J ^h   Van Zyl, J H ^h   Vetter, M N ^h   Whitby, M ^h   Winter, T A ^h   more..

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF BRESCIA   (Italy)

^e HOSPITAL DE CRUCES   (Spain)

^f INSTITUT PASTEUR   (France)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h NONE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FLUCONAZOLE; VORICONAZOLE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS DISEASE; FEMALE; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOLOGY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDIASIS; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; ESOPHAGEAL DISEASES; FEMALE; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 0035503203     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322653     Document Type: Article

References (37)

1. Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients
2. Resistant candidiasis
3. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: Three San Francisco epidemiological cohorts
4. Mycoses in AIDS patients
5. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: A prospective case-control study
6. Oropharyngeal candidiasis in patients with HIV: Suggested guidelines for therapy
7. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: A critical reassessment
8. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients
9. Oral azole drugs as systemic antifungal therapy
10. The future of antifungal therapy
11. The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy
12. Efficacy of oral fluconazole in the treatment of AIDS associated esophageal candidiasis
13. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial
14. Prospective study of fluconazole suspension for the treatment of esophageal candidiasis in patients with AIDS
15. Oral candidiasis: The clinical challenge of resistance and management
16. Resistance of Candida species to fluconazole
17. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp
18. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
19. In vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients
20. In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies
21. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis
22. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
23. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS
24. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia
25. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease
26. Use of voriconazole to treat invasive fungal infections in solid organ and bone marrow transplant recipients
27. Standardized Susceptibility Testing of Fluconazole: An International Collaborative Study
28. A randomized, double blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis
29. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy
30. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: Clinical outcomes and development of fluconazole resistance
31. Epidemiological shifts in opportunistic and nosocomial Candida infections: Mycological aspects
32. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
33. Uk-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man
34. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in acute invasive aspergillosis
35. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in chronic invasive aspergillosis
36. Current and emerging azole antifungal agents